APL 1202

Drug Profile

APL 1202

Alternative Names: APL-1202

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer Asieris Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase I Prostate cancer

Most Recent Events

  • 29 Aug 2017 APL 1202 is available for licensing as of 29 Aug 2017. http://www.asieris.cn/index/
  • 29 Aug 2017 Phase-I clinical trials in Prostate cancer in China (PO) (Asieris Pharmaceuticals pipeline, August 2017)
  • 29 Aug 2017 Efficacy and adverse events from a phase II trial in Bladder cancer (Monotherapy, Second-line therapy or greater) released by Asieris Pharmaceuticals (Asieris Pharmaceuticals website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top